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Abstract
Aims/hypothesis Hypoglycaemia is a major barrier to good glucose control in type 1 diabetes. Frequent hypoglycaemic episodes
impair awareness of subsequent hypoglycaemic bouts. Neural changes underpinning awareness of hypoglycaemia are poorly
defined and molecular mechanisms by which glial cells contribute to hypoglycaemia sensing and glucose counterregulation
require further investigation. The aim of the current study was to examine whether, and by what mechanism, human primary
astrocyte (HPA) function was altered by acute and recurrent low glucose (RLG).
Methods To test whether glia, specifically astrocytes, could detect changes in glucose, we utilised HPA and U373 astrocytoma
cells and exposed them to RLG in vitro. This allowed measurement, with high specificity and sensitivity, of RLG-associated
changes in cellular metabolism. We examined changes in protein phosphorylation/expression using western blotting. Metabolic
function was assessed using a Seahorse extracellular flux analyser. Immunofluorescent imaging was used to examine cell
morphology and enzymatic assays were used tomeasure lactate release, glycogen content, intracellular ATP and nucleotide ratios.
Results AMP-activated protein kinase (AMPK) was activated over a pathophysiologically relevant glucose concentration range.
RLG produced an increased dependency on fatty acid oxidation for basal mitochondrial metabolism and exhibited hallmarks of
mitochondrial stress, including increased proton leak and reduced coupling efficiency. Relative to glucose availability, lactate
release increased during low glucose but this was not modified by RLG. Basal glucose uptake was not modified by RLG and
glycogen levels were similar in control and RLG-treated cells. Mitochondrial adaptations to RLG were partially recovered by
maintaining euglycaemic levels of glucose following RLG exposure.
Conclusions/interpretation Taken together, these data indicate that HPA mitochondria are altered following RLG, with a met-
abolic switch towards increased fatty acid oxidation, suggesting glial adaptations to RLG involve altered mitochondrial metab-
olism that could contribute to defective glucose counterregulation to hypoglycaemia in diabetes.
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Introduction
Hypoglycaemia remains a major concern for people with type
1 diabetes and advanced insulin-treated type 2 diabetes. For
individuals with diabetes, hypoglycaemia is a major barrier to
enjoying the benefits of exercise [1, 2] and is increasingly
thought to increase the risk of cardiovascular events in both
type 1 and type 2 diabetes [3, 4]. Individuals who experience
frequent hypoglycaemia or have long-duration diabetes pro-
duce diminished counterregulatory responses (CRRs) to
hypoglycaemia [5, 6], often accompanied by reduced symp-
tom awareness, termed ‘impaired hypoglycaemia awareness’.
Defective glucose CRRs to hypoglycaemia are, at least in
part, mediated by changes in the function of critically impor-
tant glucose-sensing neurons in the ventromedial nucleus of
the hypothalamus (VMH), although glucose-sensing neurons
in the hindbrain have also been implicated [7]. In addition to
neurons, the brain contains at least as many cells that lack
electrically excitable membranes. Of these, the largest group
is the glial cells, the largest subpopulation of which are astro-
cytes. As well as exhibiting a range of cell-to-cell signalling
pathways, astrocytes are increasingly recognised as important
players in central nervous system-based diseases, such as obe-
sity [8], Alzheimer’s disease [9], Parkinson’s disease [10] and
motor neuron disease [11].
Astrocytes play an important role in regulating glucose up-
take into cerebral microvessels [12]. In addition to this role in
glucose delivery, more recent studies have demonstrated that
stimuli such as 2-deoxyglucose, that block intracellular glucose
metabolism, increase intracellular Ca2+ in hindbrain astrocytes
[13], a well-accepted marker of increased astrocyte activity, sug-
gesting a more direct role in sensing changes in glucose levels.
In the hypothalamus, astrocyte activation by fasting is indicated
by increased glial fibrillary acidic protein (GFAP) expression
and process complexity [14, 15], both markers of gliosis.
Astrocytes contain small amounts of glycogen that can be
broken down to glucose and metabolised to lactate, which is
released to feed active neurons. For example, astrocytic glyco-
gen stores canmaintain axonal activity during energetic stress in
white matter [16, 17] and also contribute to memory formation
[18, 19]. Brain glycogen concentrations are increased on recov-
ery from exercise [20], suggesting that astrocytic glycogen
stores are both physiologically and pathophysiologically regu-
lated. Astrocytes are in intimate apposition to the cerebral vas-
culature, meaning that a change in glycaemia may be detected
by astrocytes before neurons. Moreover, astrocytes are general-
ly accepted asmetabolically flexible neural cells that can rapidly
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upregulate glycolysis to support neuronal function, partly
through the higher expression of 6-phosphofructo-2-kinase type
3 (PFKFB3), which can stimulate glycolysis [21]. Despite this,
little is known about the intrinsic response of astrocytes to acute
and recurrent low glucose (RLG) that occurs in type 1 diabetes.
Given that astrocytes are metabolically flexible cells, we
hypothesised that human astrocytes would: (1) sense low
glucose by increasing phosphorylation of cellular energy
sensor AMP-activated protein kinase (AMPK); and (2) ex-
hibit altered glycolytic and mitochondrial metabolism fol-
lowing RLG. To test this, we utilised both human primary
astrocytes (HPA) and U373 astrocytoma cells and measured
directly components of glycolytic and mitochondrial metab-
olism, lactate release, glycogen levels, intracellular nucleo-
tide levels and expression of key metabolic enzymes.
Methods
Astrocyte isolation and cell culture HPAwere isolated from a
17 year old male donor from subventricular deep white matter
tissue immediately post-mortem following consent from next
of-kin and with ethical approval from the North and East
Devon Research Ethics Committee. Astrocytes were isolated
from tissue blocks as previously described [22], subcultured
and frozen stocks prepared. HPA cells were maintained in
humidified incubators with 95% O2/5% CO2 in HPA stock
media. U373 cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA, USA). See elec-
tronic supplementary material (ESM) Methods for further de-
tails of stock media components.
For experiments, the glucose concentration was reduced to
2.5 mmol/l glucose for 2 h, supplemented with 1% serum and
22.5 mmol/l mannitol for HPA cells. Glucose concentrations
were then dropped further to 0.1 mmol/l glucose as a
hypoglycaemic-like stimulus or plated at 2.5 mmol/l glucose,
supplemented with 1% (vol./vol.) serum and 24.9 mmol/l or
22.5 mmol/l mannitol, for HPA and U373 cells, respectively.
For RLG studies over 4 days, control cells were exposed to
zero bouts (2.5 mmol/l glucose instead) and RLG cells ex-
posed to 4 bouts of 3 h of 0.1 mmol/l glucose and recovered
in media containing high (HPA, 5.5 mmol/l; U373, 7.5 mmol/l)
glucose and FBS overnight (see ESM Fig. 1 for culture
model and ESM Methods for further details). The reasons
for this were twofold: (1) higher glucose levels overnight
(approximately 19 h) prevented glucose depletion from the
media, which would occur if the cells were maintained at
2.5 mmol/l; and (2) this pattern more accurately represented a
model of glucose variation seen in type 1 diabetes.
All cell lines used were verified as mycoplasma-free using
a commercial test kit (MycoAlert, Lonza, Slough, UK). Cells
were randomly assigned to experimental groups by an un-
blinded investigator (unless otherwise stated).
Immunoblotting Cellular protein was isolated as previously
described [23], with minor modifications. Briefly, for acute
studies 4.5 × 105 cells or, for RLG studies, 2.5 × 105 cells were
seeded on to 60 mm petri dishes and harvested in 65 μl lysis
buffer. Protein concentrations were assessed by Bradford as-
say. A 10 μg sample of protein was loaded per lane on 7–10%
(wt/vol.) polyacrylamide gels. Proteins were transferred to
nitrocellulose membranes, blocked with BSA (5% wt/vol.)
or powdered milk (5% wt/vol.) and probed with antibodies
against target proteins. See ESMMethods for antibody details.
Analysis of cellular metabolism HPA and U373 cells were
seeded at 2 × 104 cells per well in Seahorse XFe96 assay plates
(no. 102416-100, Agilent, Craven Arms, UK) on the day be-
fore the study. Medium was exchanged for low-buffered me-
dia, the pH adjusted to 7.40 at 37.0°C and cells placed in an
atmospheric CO2 incubator, to remove CO2 buffering capac-
ity, 1 h prior to starting the assay. Mitochondrial stress tests
(no. 103015-100, Agilent) and mitochondrial fuel flexibility
tests (no. 103270-100, Agilent) were performed as per manu-
facturer’s instructions (see ESM Methods for further details).
Samples with negative values for OCR (probably due to the
presence of an air bubble) were excluded from analysis.
Measurement of intracellular nucleotides Total ATP levels
were measured using ATPlite (no. 6016941, Perkin Elmer,
Seer Green, UK) with minor modifications as previously de-
scribed [23]. ATP/ADP ratios were assayed by luminescence
assay (no. MAK135, Sigma-Aldrich, Gillingham, UK).
Briefly, 1 × 103 cells were seeded on to black-walled 96 well
plates and exposed to 2.5 mmol/l or 0.1 mmol/l glucose levels
for 15–180 min and nucleotide ratios assayed as per manufac-
turer’s instructions.
Measurement of extracellular lactate, glucose uptake and gly-
cogen levels Extracellular lactate was measured by assessing
NADH production from NAD+ in the presence of lactate de-
hydrogenase as previously described [24]. Briefly, 100 μl of
extracellular supernatant fraction was examined against a
standard curve of lactate from 0 nmol/l to 50 nmol/l.
Glucose uptake was measured using fluorescently labelled
glucose analogue 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-6-deoxyglucose (6-NBDG; CAY13961-5/6-
NBDG, Cayman Chemical, Tallinn, Estonia). 6-NBDG
(600 μmol/l) was added for 15 min in 2.5 mmol/l glucose in
control conditions and in cells exposed to RLG. Glycogen
levels were measured using a fluorometric kit as per manufac-
turer’s instructions (no. MET-5023, Cambridge Bioscience,
Cambridge, UK).
Fluorescent imaging Mitochondrial morphology was exam-
ined by staining HPA cells with MitoTracker Red CMXRos
(50 nmol/l; M7512, no. 1785958, Thermo Fisher Scientific,
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Loughborough, UK) before fixing and imaging using confo-
cal microscopy (Leica, London, UK DMi8; ×63/oil immer-
sion lens) by an investigator blind to sample identity. See ESM
Methods for further details. To examine intermediate filament
protein expression/localisation, HPA cells were fixed and
stained with an anti-vimentin antibody (V6630, no.
102M4831, mouse, Sigma-Aldrich; 1:500 in lysine buffer)
or an anti-GFAP antibody (z0334 no. 20035994, rabbit,
Agilent; 1:100 in lysine buffer). All antibodies were validated
by the manufacturer. See ESM Methods for further details.
Statistical analysis For immunoblotting, densitometric values
were normalised to unity to examine relative fold change in
expression. A one-sample t test was used to determine signif-
icant changes in phosphorylation or expression, relative to
control. For comparisons of two groups a two-tailed unpaired
t test was used and for multiple group comparisons, a one-way
ANOVAwith post hoc Bonferroni were used. To compare the
mean differences between groups split by two independent
variables, a two-way ANOVAwith Bonferroni multiple com-
parisons tests was used. Statistical tests were performed using
GraphPad Prism software (Prism 5; GraphPad Software, La
Jolla, CA, USA). Results are expressed as mean ± standard
error, unless otherwise stated. Values of p < 0.05 were consid-
ered statistically significant.
Results
AMPK is activated by acute low glucose in human astrocytes
AMPK activation in neurons is required for sensing
hypoglycaemia [25], though it is not known whether astrocyt-
ic AMPK reacts to the same energy stress. To address this, we
exposed human astrocytes to normal (2.5 mmol/l) and low
(0.1 mmol/l) glucose levels for brain cells. In cells exposed
to low glucose for 30 min, we noted, in both the HPA (Fig. 1a,
c) and U373 cells (Fig. 1b, d), an increased phosphorylation of
AMPK at threonine 172, a site which must be phosphorylated
for full kinase activation. This was accompanied by increased
phosphorylation of acetyl-CoA carboxylase (ACC) at serine
79 (Fig. 1a, b, e, f). These novel observations in glia are con-
sistent with the ubiquitous role of AMPK in detecting low
glucose levels in other cells types. In contrast, although the
astrogliosis marker GFAP was expressed in HPA cells, its
expression appeared unaltered in cells exposed to acute low
glucose (ESM Fig. 2).
RLG exposure increases mitochondrial metabolism in human
astrocytes To determine whether baseline metabolism was
altered following RLG, we performed mitochondrial stress
tests on HPA and U373 cells (see ESM Fig. 1 for RLG
model). In order to observe any cellular adaptations, this was
performed in 2.5 mmol/l glucose, representing euglycaemic,
glucose levels following RLG.
First, we observed significantly higher baseline oxygen
consumption rate (OCR) in both HPA (Fig. 2a, c) and U373
cells (Fig. 2b, d) exposed to RLG (3 vs 0 prior bouts of low
glucose), indicating persistent adaptations in cellular metabo-
lism. Oligomycin was then added to block ATP synthase,
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
(FCCP) to stimulate maximal respiration, and rotenone and
antimycin Awere added to inhibit complex I and III, respec-
tively. This allowed calculation of coupling efficiency, which
was significantly decreased in HPA cells only (Fig. 2e, f).
However, both cell types displayed increased proton leak
(Fig. 2g, h), indicating mitochondrial dysfunction. Despite
the evidence of mitochondrial dysfunction, we saw no chang-
es in the morphology of the filamentous mitochondrial net-
works between the treatment groups, as examined using
MitoTrackerRed (ESM Fig. 3a, b).
In addition to changes in OCR, we also noted significantly
elevated basal extracellular acidification rate (ECAR), in HPA
cells exposed to RLG (Fig. 2i, k), indicating enhanced glycol-
ysis following RLG. This did not occur within U373 cells
following RLG (Fig. 2j, l).
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Fig. 1 Acute low glucose increased AMPK pathway activation.
Representative immunoblots from HPA (a; n = 8) and U373 astrocytoma
cells (b; n = 3) exposed to 2.5 or 0.1 mmol/l glucose media for 30min. (c,
d) Densitometric analysis of immunostaining for pT172 AMPK normal-
ised to actin as a loading control in HPA (c) and U373 astrocytoma cells
(d). (e, f) Densitometric analysis of immunostaining for pS79 ACC nor-
malised to actin as a loading control in HPA (e) and U373 astrocytoma
cells (f). Error bars represent SEM. *p < 0.05, one-sample t test vs control
(2.5 mmol/l glucose)
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Astrocytes exposed to RLG display enhanced glycolysis on
recovery of glucose level Given the increased basal ECAR
in HPA cells exposed to RLG, we next examined glycolyt-
ic re-activation after an acute glucose withdrawal
(~80 min) in HPA cells following prior exposure to RLG.
Under control conditions, we noted that the ECAR
(glycolysis) response to glucose was concentration depen-
dent (Fig. 3a–c), although ECAR was not significantly
higher at 5.5 mmol/l glucose than 2.5 mmol/l glucose, in-
dicating that the metabolic response to glucose is saturated
at physiological glucose levels. Interestingly, the ECAR
response to glucose in cells exposed to RLG (three bouts
of low glucose) was significantly greater than control (no
bouts of low glucose), indicating an enhanced glycolytic
capacity (Fig. 3a–c). This only occurred at euglycaemic
and hyperglycaemic levels. Consistent with enhanced gly-
colytic activity, we also noted a significant reduction in
OCR following glucose injection, indicative of a shift
away from mitochondrial metabolism towards glycolysis
(Fig. 3d–f). Correspondingly, the reduction in OCR fol-
lowing glucose recovery was augmented in HPA cells ex-
posed to RLG. Taken together, these data suggest an en-
hanced Warburg-like effect in HPA cells following recov-
ery of glucose levels. In U373 cells, RLG did not alter
ECAR between groups (control vs RLG) on glucose recov-
ery. However, the re-activation of ECAR on delivery of
glucose was not concentration dependent and in U373 cells
the relative increase in ECAR was twice as large as that in
HPA cells (ESM Fig. 4). These studies highlight clear dif-
ferences between primary cells, obtained from source, with
those of transformed cells which should be taken into con-
sideration when designing experiments.
Fatty acid oxidation is increased in human astrocytes follow-
ing RLG To assess potential changes to mitochondrial fuel
usage following RLG, we performed mitochondrial fuel flex-
ibility tests, achieved by sequential selective inhibition of mi-
tochondrial pyruvate carrier (MPC; glucose oxidation path-
way), glutaminase (glutamine oxidation pathway) and carni-
tine palmitoyltransferase 1 (CPT1; fatty acid oxidation path-
way). Surprisingly, there was no change in mitochondrial de-
pendency, capacity or flexibility to metabolise pyruvate in
HPA cells (Fig. 4a–c). This suggests that in astrocytes, alter-
ations to glucose metabolism are upstream of the transport of
pyruvate into the mitochondria. There was a non-significant
trend towards reduced glutamine dependency at baseline fol-
lowing RLG (Fig. 4d), with no significant change to the glu-
tamine oxidation capacity (Fig. 4e). Combined, this produced
a significant increase in glutamine flexibility (Fig. 4f).
Interestingly, RLG significantly increased metabolic depen-
dency on fatty acids but with no change in fatty acid oxidation
(FAO) maximum capacity, thereby causing a decrease in flex-
ibility (Fig. 4g–i). These data demonstrate that RLG induces
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Fig. 2 RLG increased baseline mitochondrial metabolism and reduced
mitochondrial coupling efficiency in HPA (a,c,e,g,i,k) and U373 astrocy-
toma cells (b,d,f,h,j,l). (a, b) OCR of HPA (a; control, n = 36; RLG, n =
39, across three separate assays) and U373 cells (b; control, n = 40; RLG,
n = 43, across three separate assays) following RLG. Cells were exposed
to oligomycin (10 μmol/l), FCCP (5 μmol/l) and a combination of rote-
none and antimycin A (5 μmol/l). (c, d) Mean basal OCR in control and
RLG-treated astrocytes. (e, f) Coupling efficiency calculated from the
ratio of oligomycin-sensitive OCR and basal OCR expressed as a per-
centage. (g, h) Proton leak, calculated from the oligomycin-insensitive
(i.e. not ATP synthase linked) OCRminus non-mitochondrial respiration.
(i, j) ECAR analysis measured during mitochondrial stress tests. (k, l)
Mean baseline ECAR following RLG. Error bars represent SEM.
*p < 0.05, **p < 0.01 and ***p < 0.001, unpaired two-tailed student’s t
test vs control. mpH, milli-pH; Oligo, oligomycin; R/A, rotenone and
antimycin A
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mitochondrial adaptations to fuel sources, consistent with a
shift towards increased reliance on FAO and an enhanced
flexibility to utilise glutamine.
Human astrocytes maintain energy production (total ATP and
ATP/ADP ratio) during low glucose conditions To examine the
consequences of acute low glucose and RLG for astrocyte
energy content, we measured total ATP and ATP/ADP ratios.
These measurements were made both in the presence of acute
low glucose and following RLG. Interestingly, total ATP
levels did not significantly change in HPA (Fig. 5a) or U373
cells (Fig. 5b) during acute low glucose exposure (0.1 mmol/l)
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Fig. 4 RLG altered HPA mitochondrial fuel flexibility to increase depen-
dency on fatty acids for basal oxidation. (a–c) Inhibition of MPC using
UK5099 (2 μmol/l) to measure dependency (a), maximum capacity (b)
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FAO pathway following RLG. Dependency: contribution of that pathway
to baseline OCR. Capacity: maximum ability to oxidise through that
pathway when two other oxidative pathways are inhibited. Flexibility:
calculated from the difference between dependency and capacity.
Control, n = 21; RLG, n = 24. Error bars represent SEM. *p < 0.05, un-
paired two-tailed Student’s t test vs control. FA, fatty acid; Glc, glucose;
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Fig. 3 RLG increased glycolytic
re-activation after acute low
glucose exposure. (a–c) ECAR
increased in HPA cells on re-
introduction of 0.5 mmol/l
glucose (a), 2.5 mmol/l glucose
(b) and 5.5 mmol/l glucose (c).
(d–f) OCR decreased on addition
of 0.5 mmol/l glucose (d),
2.5 mmol/l glucose (e) and
5.5 mmol/l glucose (f). Dashed
line, control; solid line, RLG.
Control, n = 8–10; RLG, n = 9–
10. Error bars represent SEM.
*p < 0.05; **p < 0.01 and
***p < 0.001, unpaired two-tailed
student’s t test vs control. Glu,
glucose; mpH, milli-pH
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lasting 3 h. Despite the increased basal mitochondrial and
glycolytic metabolism described above, total ATP levels fol-
lowing RLG were also comparable with control (Fig. 5a, b).
Similarly, the ATP/ADP ratio was not significantly different
following 3 h of 0.1 mmol/l glucose, nor was the basal ratio
altered following RLG (Fig. 5c, d). These data indicate that
the total ATP content and ATP/ADP ratio are well maintained
in astrocytes, at least in response to up to 3 h of low glucose,
and that changes to glycolytic and mitochondrial metabolism
may be compensatory to sustain intracellular nucleotide
levels.
RLG does not alter glucose uptake or glycogen levels in hu-
man astrocytes Western blotting demonstrated that the levels
of key glycolytic markers GLUT1, hexokinase (HK)I, HKII,
HKIII and phosphofructokinase [platelet] (PFK[P]) were not
altered by acute or RLG in human astrocytes (ESM Fig. 5).
Lactate release modestly decreased from HPA cells and sig-
nificantly decreased from U373 cells during 3 h of low glu-
cose exposure (Fig. 6a, b), although the decrease was propor-
tionally less than the 25-fold reduction in glucose availability.
Hence, when corrected for glucose availability, there was a
relative increase in lactate release (Fig. 6c, d); however, this
was not different between control and RLG-treated cells.
We next assessed the degree of glucose uptake by human
astrocytes using the fluorescently labelled glucose analogue,
6-NBDG. HPA cells exposed to RLG showed no change in 6-
NBDG uptake (Fig. 6e), indicating that the persistent changes
in mitochondrial oxygen consumption were not simply medi-
ated by increased glucose uptake. Correspondingly, we did
not observe any changes in astrocytic glycogen content fol-
lowing RLG (Fig. 6f).
Correlating with our mitochondrial imaging studies, the
levels of mitochondrial markers succinate dehydrogenase
(SDH) and the voltage-dependent anion channel (VDAC)
were not altered by RLG, suggesting no change in total
mitochondrial content (ESM Fig. 5). Fatty acid synthase
(FAS) and CPT-1a expression were also not altered, indicat-
ing that changes in fatty acid-dependency following RLG
are likely to be mediated by metabolic flux/activity rather
than alternations in expression of enzymes within the FAO
pathway.
Partial recovery of metabolic changes by maintenance of glu-
cose levels To assess whether mitochondrial changes induced
by RLG were reversible, we exposed cells to RLG and intro-
duced a 4 day recovery period where glucose levels were
maintained at 2.5 mmol/l glucose following the last bout of
low glucose exposure. As previously, our RLG treatment
group had elevated basal OCR, increased proton leak and
elevated basal ECAR (Fig. 7). Following recovery, basal mi-
tochondrial OCR returned to levels comparable with control
(Fig. 7a, b). In contrast, coupling efficiency was still reduced
(Fig. 7c) and proton leak showed a trend towards recovery,
which did not reach statistical significance (Fig. 7d). RLG-
induced elevated basal ECAR was largely unchanged follow-
ing recovery (Fig. 7e, f).
Discussion
Our studies shed new light on the previously uncharacterised
intrinsic metabolic changes in human glial cells in response to
acute and recurrent low glucose. We demonstrate that astro-
cytes, in the absence of physical and chemical signals from
neurons, react to low glucose by increasing the activation of
the key metabolic sensor AMPK. Changes in AMPK pathway
phosphorylation occur within a pathophysiologically relevant
glucose concentration range, similar to that which affects CNS
glucose-sensing neurons [26].
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Fig. 5 Acute and recurrent low
glucose did not modify
intracellular ATP or ATP/ADP
ratios. (a, b) Total intracellular
ATP levels in HPA (a, n = 6) and
U373 astrocytoma cells (b; n = 6)
exposed to different glucose
concentrations for 3 h. (c, d)
Intracellular ATP/ADP ratios in
HPA (c; n = 6) and U373
astrocytoma cells (d; n = 4)
exposed to 2.5 or 0.1 mmol/l
glucose for 3 h. One-way
ANOVAwith post hoc Bonferroni
multiple comparisons tests. Glu,
glucose; tATP, total ATP
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It is well accepted that astrocytes are more metabolically
flexible than neurons, partly because of the higher expression
of PFKFB3, which can accelerate glycolysis during metabolic
stress [21]. Therefore, to examine specifically the changes in
astrocyte metabolism following RLG, we measured markers
of mitochondrial and glycolytic metabolism in HPAmonocul-
tures. Importantly, we found that daily prior bouts of low
glucose (4 × 0.1 mmol/l glucose), lasting 3 h, were sufficient
to increase basal mitochondrial and glycolytic metabolism to
sustain intracellular ATP supply. Increased basal mitochondri-
al metabolism is likely mediated, at least in part, by an in-
creased contribution of FAO to basal oxygen consumption.
Correlating with this hypothesis, we noted increased mito-
chondrial proton leak and reduced mitochondrial coupling
efficiency in astrocytes exposed to RLG. Importantly, FAO
is known to increase uncoupling, as FAO generates increased
levels of reactive oxygen species (ROS)/superoxide [27] that
can increase proton leak via activation of uncoupling proteins
or the ATP/ADP antiporter (ANT; [28]). Previous work has
demonstrated that, in vivo, genes for β-oxidation are induced
by acute hypoglycaemia, but this fails following recurrent
hypoglycaemia [29]. Our data in astrocyte monocultures con-
trast with these measurements taken from rodent mediobasal
hypothalamus, which include both neurons and glia and axon
projections tracking through the dissected area. Therefore, it is
possible that cell-type-specific changes are masked when
measuring mRNA expression from whole-tissue sections.
A previous study demonstrated that low intracellular glu-
cose levels caused by loss of insulin receptors on astrocytes
(leading to reduced astrocytic glucose transport) resulted in
astrocytic mitochondria that were smaller and less numerous
[30], suggesting increased mitophagy. In our study, despite
evidence of mitochondrial stress and in contrast to our expec-
tation, examination of the filamentous mitochondrial net-
works revealed no change in either mitochondrial size or num-
ber following acute low glucose or RLG. Indeed, mitochon-
dria exposed to RLG generally displayed a normal filamen-
tous network, with little or no evidence of mitochondrial frag-
mentation. These data suggest that astrocyte mitochondria
successfully adapt to maintain energy production in response
to repeated bouts of low glucose availability. It is possible that
the relatively acute reductions in glucose availability in our
experiments were a mild stress, insufficient to cause gross
changes in mitochondrial morphology. Moreover, cells were
recovered into solutions containing serum, likely providing
sufficient insulin/growth factor receptor activation to aid re-
covery from the acute stress. Therefore, it is possible that
reductions in insulin receptor activation, rather than just intra-
cellular glucose deprivation per se, may mediate the altered
mitochondrial morphology reported previously. A similar
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Fig. 6 RLG does not alter lactate
release, glucose uptake or
glycogen levels in HPA. (a, b)
Extracellular lactate levels
measured from conditioned
media from HPA (a; n = 8) and
U373 (b; n = 6) following
exposure to 2.5 or 0.1 mmol/l
glucose-containing media for 3 h.
(c, d) Extracellular lactate levels
normalised to glucose availability
from conditioned media from
HPA (c; n = 8) and U373 (d; n =
6) following exposure to 2.5 or
0.1 mmol/l glucose-containing
media for 3 h. (e) Fluorescent
signal from labelled glucose
analogue 6-NBDG incubated
with HPA cells for 15 min. (f)
Glycogen content of HPA cells in
control and following exposure to
RLG (n = 5). *p < 0.05,
**p < 0.01 and ***p < 0.001,
one-way ANOVAwith post hoc
Bonferroni multiple comparisons
tests, and unpaired two-tailed
Student’s t test. RFU, relative
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phenotype of increased mitochondrial fragmentation was also
reported using inducible knockdown of insulin-like growth
factor 1 (IGF-1) receptors on astrocytes [31], suggesting an
important role for hormones in regulating glial cell mitochon-
drial function that requires further investigation.
Previous studies in rats found no change in brain glycogen
levels following recurrent hypoglycaemia [32] or any correla-
tion between brain glycogen content and impaired awareness
of hypoglycaemia in humans [33]. However, other studies
suggest brain glycogen content is increased following recov-
ery from insulin-induced hypoglycaemia [34] and following
recurrent 2-deoxyglucose-induced glucoprivation (reduction
in utilisable glucose) in mice [35]. Our data clearly demon-
strate that astrocytes intrinsically adapt by increasing cellular
metabolism in response to recurrent energy stress. Specifically,
rates of extracellular acidification (a marker for glycolysis)
following glucose ‘reperfusion’were elevated in cells exposed
to RLG, suggesting an augmented re-activation of glycolysis.
However, despite glycolysis being a major determinant of gly-
cogen synthesis, we found no significant change in astrocytic
glycogen levels following RLG. Extracellular lactate, which
can be generated from glycogen breakdown during
aglycaemia [17], increased substantially, relative to glucose
availability, during low glucose exposure, though the magni-
tude of this response was not significantly altered following
RLG. We cannot rule out, however, the possibility that more
subtle changes in lactate and glycogen occur during the tran-
sition to low glucose or on glucose recovery. Moreover, before
definitively ruling out a role for astrocytic glycogen and sub-
sequent lactate release, a more replete in vitro model, contain-
ing both astrocytes and neurons, should be tested, thus facili-
tating the inclusion of neurotransmitter dynamics in themodel.
The ability to produce increasingly credible human neurons
and astrocytes from inducible pluripotent stem cell (iPSC)
sources could potentially enable such investigations to be per-
formed in an in vitro human system, overcoming some of the
physiological limitations of mono-culture systems.
Astrocytes play a key role in maintaining glutamatergic
neurotransmission through the glutamate−glutamine cycle
(for recent review see Schousboe [36]). Importantly, astrocytic
glutamate clearance requires co-transport of three Na+ ions
[37], meaning that, via the ATP-dependent Na+/K+ ATPase,
there is a significant metabolic cost for astrocytes to maintain
their Na+ homeostasis, estimated to account for approximately
20% of total astrocytic ATP production [38]. This process may
become particularly costly during hypoglycaemia. Moreover,
glutamate stimulation of astrocytes produces mitochondrial
dysfunction, decreasing mitochondrial spare respiratory ca-
pacity and increasing lactate production [39]. Furthermore,
recent observations suggest that astrocytic glutamate recycling
is diminished following recurrent hypoglycaemia, a change
most likely mediated by reduced astrocyte glutamate uptake
[40]. Interestingly, recurrent hypoglycaemia is associated with
relative GABA excess within the VMH [41]. In addition to
glutamate, astrocytes also clear GABA from the extracellular
space [42], which is energetically less expensive for the astro-
cytes than glutamate recycling [43]. This raises the interesting
possibility that the glutamatergic failure and relative GABA
excess following recurrent hypoglycaemia may be mediated
by astrocytes, plausibly as a protective mechanism against
excitotoxicity, although further study is required.
Our data add to published findings and suggest that meta-
bolic changes within astrocytes could be protective adapta-
tions to limit brain cell damage or contribute to defective
counterregulatory responses following RH. In support of the
latter, astrocytes are increasingly recognised as playing an im-
portant role in the regulation of whole-body metabolism. For
example, chemogenetic activation (by increasing intracellular
Ca2+) of astrocytes in the arcuate nucleus increases feeding in
mice and, conversely, sequestering astrocytic Ca2+ decreases
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Fig. 7 Maintaining glucose levels following RLG partially recovered
metabolic adaptations. (a) OCR of HPA following RLG with a 4 day
recovery after the last low glucose exposure (control, n = 31; RLG, n =
31; RLG + recovery, n = 26). Cells were exposed to oligomycin
(10 μmol/l), FCCP (5 μmol/l) and a combination of rotenone and
antimycin A (5 μmol/l). (b) Mean basal respiration rate (OCR). (c)
Coupling efficiency calculated from the ratio of oligomycin-sensitive
OCR and basal OCR expressed as a percentage. (d) Proton leak, calcu-
lated from the oligomycin-insensitive (i.e. not ATP synthase-linked) OCR
minus non-mitochondrial respiration, from HPA cells; RLG + recovery
was not significant vs control or vs RLG. (e) ECAR analysis measured
during mitochondrial stress tests (control, n = 31; RLG, n = 31; RLG +
recovery, n = 26). (f) Mean baseline ECAR in HPA cells following RLG
and RLG + recovery. Error bars represent standard error of the mean.
*p < 0.05, **p < 0.01 vs control. Analyses used unpaired two-tailed
Students t tests. RLG + Rec, RLG + recovery
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food intake [14]. Moreover, astrocytes can be a source of pro-
inflammatory cytokines in the brain [44], including TNFα,
which has previously been reported to blunt glucose-sensing
glucose-inhibited neurons [45], suggesting that pro-
inflammatory signals from astrocytes may regulate energy-
sensing neurons of the hypothalamus [44]. Accordingly, mod-
ulation of inflammatory signalling in astrocytes modulates
feeding in response to a high-fat diet [46]. Within the hind-
brain, astrocytes can detect hypoglycaemia to regulate adja-
cent neurons to increase gastric emptying in response to a
glucoprivic stimulus [13]. Astrocytes have also been shown
to decrease hyperglycaemia in a rodent model of type 1 dia-
betes [47], suggesting that astrocytes may play fundamental
roles in regulating whole-body glucose levels. It should also
be noted that there is significant heterogeneity in astrocytes
across different brain regions. For example, hypothalamic as-
trocytes express more genes for lipid oxidation compared with
cortical astrocytes, which express more genes for lipid synthe-
sis [48]. Regional differences in astrocytic glycogen content
also exist, with high levels in hippocampus and cortex and
comparatively lower levels in subcortical structures [49].
Within the hindbrain, only a subset of astrocytes respond to
a glucoprivic stimulus [50], indicating that not all astrocytes
will respond to a given stimulus in the samemanner. Given the
significant heterogeneity of neurons within the hypothalamus,
it is plausible that subtypes of astrocytes within this region
may contribute distinct roles in hypoglycaemia sensing.
However, the territory of a single astrocyte is likely to overlap
with multiple neuronal types, probably requiring subcellular
site-specific responses.
In conclusion, our data further support the evidence that
glial cells detect hypoglycaemic stress. Moreover, we demon-
strate that mitochondrial function (increased FAO) in human
astrocytes is altered by RLG. These data suggest a possible
role for glial mitochondrial adaptations in defective glucose
counterregulation or protection against hypoglycaemia, and
highlight the need for more investigation into neuron-glial
interactions during and following recurrent hypoglycaemia.
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